文献速递心外重症与机械循环支持

儿童心内持续流左心室辅助系统的结局

Outcomes of children supported with an intracorporeal continuous-flow left ventricular assist system.
PubMed 文献 · J Heart Lung Transplant · 2018-09-25

该研究基于Intermacs/Pedimacs注册数据,分析了2012年9月至2017年6月192例儿童和247例年轻成人使用HeartWare持续流左心室辅助装置的结局。儿童与年轻成人总生存无统计学差异,但儿童不良事件常见,且体重<20 kg儿童出院率仅33%。

要点

  • 儿童使用HeartWare持续流LVAD的生存与年轻成人相当
  • 儿童感染、设备故障/泵血栓等不良事件发生率仍较高
  • 体重<20 kg儿童出院率低(33%),需关注出院障碍

核心结论

  • 儿童使用HeartWare持续流左心室辅助装置生存率令人鼓舞,与年轻成人相当,但不良事件并不少见。
  • 需持续评估儿童使用HeartWare以降低不良事件并了解出院障碍。

研究设计与样本

  • 回顾性注册研究,纳入2012年9月至2017年6月Intermacs和Pedimacs注册中<19岁儿童192例及19-30岁年轻成人247例,均使用HeartWare装置。
  • 比较两组不良事件和结局。

主要发现

  • 儿童中位体重51.5 kg(范围13.1-162),年轻成人75.8 kg(范围29.8-191),p≤0.0001。
  • 儿童中位体表面积1.5 m2(范围0.6-2.9),年轻成人1.9 m2(范围1.1-3.2),p≤0.0001。
  • 植入时12例儿童体重<20 kg,其中58.3%有先天性心脏病,而体重≥20 kg儿童为11.7%,年轻成人为6.1%(p≤0.0001)。
  • 儿童中位支持时间2.8个月(IQR 1.3-6.0),年轻成人9.7个月(IQR 4.0-19.2),p≤0.0001。
  • 儿童与年轻成人严重不良事件:感染27% vs 44%(p=0.0002),大出血23% vs 23%(p=0.9),设备故障/泵血栓11% vs 19.0%(p=0.04),卒中10% vs 12%(p=0.5)。

关键数值与推荐

  • 儿童与年轻成人总生存无统计学差异,体重<20 kg儿童死亡率未增加。
  • 出院率:年轻成人80%,体重≥20 kg儿童48%,体重<20 kg儿童33%。
  • 体重<20 kg儿童中,大出血0%,感染16.7%,卒中8.3%。

临床怎么用

  • 儿童使用HeartWare持续流LVAD可作为桥接或 destination 治疗选择,生存与年轻成人相当。
  • 需警惕儿童感染、设备故障/泵血栓等不良事件,尤其低体重儿童出院率低,应优化出院管理。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since 2012, there has been growing use of the HeartWare (Medtronic, Mounds View, MN) intracorporeal continuous flow (CF) ventricular assist device (VAD) in children, despite it not being labeled for use in pediatric patients. We sought to describe the use and outcomes of children with HeartWare VADs. METHODS: We identified all patients aged < 19 years and young adults aged 19 to 30 years supported with HeartWare who were entered into the pediatric portion (Pedimacs) of the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) and the Intermacs registries, respectively, between September 2012 and June 2017. Adverse events and outcomes were analyzed and compared. RESULTS: We identified 192 children and 247 young adult HeartWare patients. Baseline characteristics of children differed from young adults, with lower median weight of 51.5 kg (range, 13.1-162) vs 75.8 kg (range, 29.8-191; p ≤ 0.0001) and body surface area of 1.5 m2 (range, 0.6-2.9 m2) vs 1.9 m2 (range, 1.1-3.2 m2; p ≤ 0.0001) . At the time of implant, 12 children weighed < 20 kg, and 58.3% of these children had congenital heart disease compared with 11.7% in children who weighed ≥ 20 kg and 6.1% in young adults (p ≤ 0.0001). Median duration of support was 2.8 months (IQR, 1.3-6.0 months) in children and 9.7 months (IQR 4.0-19.2 months) in young adults (p ≤ 0.0001). Serious adverse events in children and young adults included infection in 27% and 44% of patients, respectively (p=0.0002), major bleeding in 23% and 23%, respectively (p = 0.9), device malfunction/pump thrombosis in 11% and 19.0%, respectively (p = 0.04), and stroke in 10% and 12%, respectively (p = 0.5). Of the children who weighed < 20 kg at time of implant, 0% had major bleeding, 16.7% had infections, and 8.3% had stroke. Overall survival was not statistically different between children and young adults, and there was no increased mortality in children who weighed < 20 kg. Rate of discharge on HeartWare was 80% in young adults vs 48% in children who weighed ≥ 20 kg and only 33% in children who weighed < 20 kg. CONCLUSIONS: Survival in children supported with HeartWare is encouraging and comparable to young adults; however, adverse events are not uncommon in children. Ongoing evaluation of the HeartWare use in children is necessary to further decrease the rate of adverse events and understand obstacles to discharge.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. VanderPluym CJ, Adachi I, Niebler R, et al. Outcomes of children supported with an intracorporeal continuous-flow left ventricular assist system. J Heart Lung Transplant. 2018. PMID: 30391197. doi:10.1016/j.healun.2018.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。